Sirolimus for treatment of verrucous venous malformation: A retrospective cohort study - 14/01/19
Doi : 10.1016/j.jaad.2018.07.014
Gaolei Zhang, MD, PhD a, ⁎ 
, Hongguang Chen, MD, PhD b, Zhen Zhen, MD c, Jianyou Chen, MD a, Sheng Zhang, MMSc a, Qin Qin, BMS a, Xiaoyan Liu, MD, PhD a
, Hongguang Chen, MD, PhD b, Zhen Zhen, MD c, Jianyou Chen, MD a, Sheng Zhang, MMSc a, Qin Qin, BMS a, Xiaoyan Liu, MD, PhD a a Department of Dermatology and Venereology, Capital Institute of Pediatrics, Beijing, China
b Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China
c Department of Otolaryngology, Peking University First Hospital, Beijing, China
∗Correspondence to: Gaolei Zhang, MD, PhD, Department of Dermatology and Venereology, Capital Institute of Pediatrics, No 2 YaBao St, ChaoYang District, Beijing 100020, ChinaDepartment of Dermatology and VenereologyCapital Institute of PediatricsNo 2 YaBao StChaoYang DistrictBeijing100020China
| Drs Chen and Zhen contributed equally to the first author. |
|
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 80 - N° 2
P. 556-558 - février 2019 Retour au numéro
Article précédent
- Chronic nonmelanoma skin cancers and health-related impairment: A case-control study
- Adam Sutton, Ashley Crew, Shauna Higgins, Andrew Kwong, Ashley Wysong
- Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases
- Barbara Brégeon, Claire Bernier, Nicolas Josselin, Lucie Peuvrel, Marie Le Moigne, Mélanie Saint-Jean, Gaëlle Quéreux
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?